{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T22:43:28Z","timestamp":1789685008049,"version":"4.0.1"},"reference-count":73,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T00:00:00Z","timestamp":1723766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Bullous pemphigoid (BP) is an autoimmune disease characterized by the appearance of very pruritic subepidermal blisters. It appears mostly in the elderly and is associated with multiple comorbidities, which makes its management and treatment difficult. The purpose of this systematic review is to compile current information on published cases of BP treated with omalizumab (omalizumab) and dupilumab (dupilumab) in order to obtain information on clinical efficacy and safety data available. Methods: A literature search of all cases of BP treated with omalizumab\/dupilumab published in the literature up to January 2024 was performed using the Pubmed database. After an exhaustive search, a total of 61 studies encompassing 886 patients met the inclusion criteria and were included in the review. Results: The majority of patients with BP treated with omalizumab\/dupilumab presented a significant improvement in symptomatology, being very safe drugs with minimal side effects. The main limitation of the presented review is the quality of the included studies, most of them being case series or individual cases. The development of studies with a higher level of scientific evidence in the near future would be of great interest. Conclusions: Both omalizumab and dupilumab appear to be effective options for treating BP in patients refractory to other pharmacological therapies. They are drugs with a good safety profile and the adverse reactions associated with their use are infrequent and generally mild.<\/jats:p>","DOI":"10.3390\/jcm13164844","type":"journal-article","created":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T12:40:07Z","timestamp":1723812007000},"page":"4844","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Omalizumab and Dupilumab for the Treatment of Bullous Pemphigoid: A Systematic Review"],"prefix":"10.3390","volume":"13","author":[{"given":"Elena","family":"Granados-Betancort","sequence":"first","affiliation":[{"name":"School of Medicine, University of Granada, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3626-1558","authenticated-orcid":false,"given":"Manuel","family":"S\u00e1nchez-D\u00edaz","sequence":"additional","affiliation":[{"name":"Skin Autoimmune Diseases Unit, Hospital Universitario Virgen de las Nieves, 18002 Granada, Spain"},{"name":"Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitaria IBS Granada, 18002 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-8823-5575","authenticated-orcid":false,"given":"Daniel","family":"Mu\u00f1oz-Barba","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitaria IBS Granada, 18002 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4186-1435","authenticated-orcid":false,"given":"Salvador","family":"Arias-Santiago","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitairo Virgen de las Nieves, Instituto de Investigaci\u00f3n Biosanitaria IBS Granada, 18002 Granada, Spain"},{"name":"School of Medicine, Dermatology Deparment, University of Granada, 18071 Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"key":"ref_1","first-page":"328","article-title":"Bullous pemphigoid: Clinical practice guidelines","volume":"105","year":"2014","journal-title":"Actas Dermosifiliogr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"An. Bras. Dermatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4103\/0378-6323.82398","article-title":"Bullous pemphigoid","volume":"77","author":"Khandpur","year":"2011","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1111\/jdv.18220","article-title":"Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV)","volume":"36","author":"Borradori","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Huttelmaier, J., Benoit, S., and Goebeler, M. (2023). Comorbidity in bullous pemphigoid: Up-date and clinical implications. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1196999"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1001\/archderm.1996.03890270044006","article-title":"Drugs associated with bullous pemphigoid. A case-control study","volume":"132","author":"Joly","year":"1996","journal-title":"Arch. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.det.2011.03.010","article-title":"Clinical features and practical diagnosis of bullous pemphigoid","volume":"29","author":"Schmidt","year":"2011","journal-title":"Dermatol. Clin."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","article-title":"Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment","volume":"18","author":"Bernard","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Arch. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0190-9622(99)70156-8","article-title":"Low-dose oral pulse methotrexate as monotherapy in elderly patients with bullous pemphigoid","volume":"40","author":"Heilborn","year":"1999","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of the Literature","volume":"20","author":"Kremer","year":"2019","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaad.2020.01.089","article-title":"Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series","volume":"83","author":"Abdat","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e14160","DOI":"10.1111\/dth.14160","article-title":"Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid efficiently treated with omalizumab","volume":"33","author":"Garrido","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.annonc.2021.02.016","article-title":"IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies","volume":"32","author":"Barrios","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2","DOI":"10.5070\/D328257396","article-title":"A case of nivolumab-induced bullous pemphigoid successfully treated with dupilumab","volume":"28","author":"Bruni","year":"2022","journal-title":"Dermatol. Online J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e15623","DOI":"10.1111\/dth.15623","article-title":"Dupilumab for the treatment of pembrolizumab-induced bullous pemphigoid: A case report","volume":"35","author":"Pop","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/1346-8138.16678","article-title":"Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid","volume":"50","author":"Kwon","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Yan, T., Xie, Y., Liu, Y., Shan, Y., Wu, X., Wang, J., Zuo, Y.-G., and Zhang, Z. (2023). Dupilumab effectively and rapidly treats bullous pemphigoid by inhibiting the activities of multiple cell types. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1194088"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"111157","DOI":"10.1016\/j.intimp.2023.111157","article-title":"Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study","volume":"125","author":"Huang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1684\/ejd.2019.3501","article-title":"Methotrexate is safe and efficient as long-term treatment for bullous pemphigoid","volume":"29","author":"Delaumenie","year":"2019","journal-title":"Eur. J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1111\/bjd.20593","article-title":"International multicentre observational study to assess the efficacy and safety of a 0\u00b75 mg kg\u22121 per day starting dose of oral corticosteroids to treat bullous pemphigoid","volume":"185","author":"Bastos","year":"2021","journal-title":"Br. J. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Oren-Shabtai, M., Mimouni, D., Nosrati, A., Atzmony, L., Kaplan, B., Barzilai, A., and Baum, S. (2023). Biological treatment for bullous pemphigoid. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1157250"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Cao, P., Xu, W., and Zhang, L. (2022). Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.928621"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1177\/12034754221089267","article-title":"Omalizumab for the Treatment of Bullous Pemphigoid: A Systematic Review of Efficacy and Safety","volume":"26","author":"Gabrielli","year":"2022","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Jafari, S.M.S., Feldmeyer, L., Bossart, S., Simon, D., Schlapbach, C., and Borradori, L. (2021). Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.611549"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e15946","DOI":"10.1111\/dth.15946","article-title":"Omalizumab as a corticosteroid-sparing agent in the treatment of bullous pemphigoid","volume":"35","author":"Vassallo","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e539","DOI":"10.1111\/jdv.17999","article-title":"Efficacy and safety of methotrexate, omalizumab and dupilumab for bullous pemphigoid in patients resistant or contraindicated to oral steroids. A monocentric real-life study","volume":"36","author":"Velin","year":"2022","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.jaad.2014.04.053","article-title":"Omalizumab therapy for bullous pemphigoid","volume":"71","author":"Yu","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Jafari, S.M.S., Gadaldi, K., Feldmeyer, L., Yawalkar, N., Borradori, L., and Schlapbach, C. (2019). Effects of Omalizumab on Fc\u03b5RI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.01919"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Alexandre, M., Bohelay, G., Gille, T., Le Roux-Villet, C., Soued, I., Morin, F., Caux, F., Grootenboer-Mignot, S., and Prost-Squarcioni, C. (2022). Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series of 13 Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.874108"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.clim.2018.12.015","article-title":"IgE blockade in autoimmunity: Omalizumab induced remission of bullous pemphigoid","volume":"198","author":"James","year":"2019","journal-title":"Clin. Immunol."},{"key":"ref_32","first-page":"947","article-title":"Successful Omalizumab Therapy for Bullous Pemphigoid Despite Transient Reaction","volume":"18","author":"Ewy","year":"2019","journal-title":"J. Drugs Dermatol. JDD"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/ejhpharm-2020-002418","article-title":"Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient","volume":"28","year":"2021","journal-title":"Eur. J. Hosp. Pharm."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1111\/jdv.13758","article-title":"Successful treatment of bullous pemphigoid with omalizumab as corticosteroid-sparing agent: Report of two cases and review of literature","volume":"30","author":"Balakirski","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1111\/jdv.17229","article-title":"Omalizumab: An underutilized treatment option in bullous pemphigoid patients with co-morbidities","volume":"35","author":"De","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/0378-6323.183628","article-title":"Bullous pemphigoid successfully treated with omalizumab","volume":"82","author":"Keseroglu","year":"2016","journal-title":"Indian J. Dermatol. Venereol. Leprol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jdcr.2020.01.002","article-title":"Increasing evidence for omalizumab in the treatment of bullous pemphigoid","volume":"6","author":"Lonowski","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"284","DOI":"10.2340\/00015555-2845","article-title":"Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid","volume":"98","author":"Menzinger","year":"2018","journal-title":"Acta Derm. Venereol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/CCID.S373682","article-title":"Case Report: Omalizumab Successfully Treated Recalcitrant Bullous Pemphigoid in an Elderly Patient with Multiple Comorbidities","volume":"15","author":"Liu","year":"2022","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7754\/Clin.Lab.2013.130642","article-title":"Anti-IgE monoclonal antibody (omalizumab) is effective in treating bullous pemphigoid and its effects on soluble CD200","volume":"60","author":"Yalcin","year":"2014","journal-title":"Clin. Lab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1001\/archdermatol.2012.1604","article-title":"Successful treatment of bullous pemphigoid with omalizumab","volume":"148","author":"London","year":"2012","journal-title":"Arch. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4103\/idoj.IDOJ_438_19","article-title":"Complete Remission in a Patient with Treatment Refractory Bullous Pemphigoid after a Single Dose of Omalizumab","volume":"11","author":"Sardana","year":"2020","journal-title":"Indian Dermatol. Online J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1365-2133.2011.10748.x","article-title":"Successful management of severe infant bullous pemphigoid with omalizumab","volume":"166","author":"Dufour","year":"2012","journal-title":"Br. J. Dermatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2008.11.035","article-title":"Pathogenicity of IgE in autoimmunity: Successful treatment of bullous pemphigoid with omalizumab","volume":"123","author":"Fairley","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4103\/ijd.IJD_128_20","article-title":"Biologics Beyond Boundaries: Innovative Use of Biologics in Dermatology","volume":"66","author":"De","year":"2021","journal-title":"Indian J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/bjd\/ljad369","article-title":"Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: A French national multicentre retrospective study of 100 patients","volume":"190","author":"Chebani","year":"2024","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Russo, R., Capurro, N., Cozzani, E., and Parodi, A. (2022). Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?. J. Clin. Med., 11.","DOI":"10.3390\/jcm11123367"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of Dupilumab in Patients with Bullous Pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Xu, Q., Chen, L., Chen, J., Zhang, J., Zou, Y., Gong, T., and Ji, C. (2021). Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.738907"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"109788","DOI":"10.1016\/j.intimp.2023.109788","article-title":"Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review","volume":"116","author":"Liang","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.jaad.2023.03.036","article-title":"Long-term treatment outcomes and safety of dupilumab as a therapy for bullous pemphigoid: A multicenter retrospective review","volume":"89","author":"Learned","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e924","DOI":"10.1002\/iid3.924","article-title":"Concomitant use of dupilumab with glucocorticoid in bullous pemphigoid reduces disease severity: A preliminary study","volume":"11","author":"Hu","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"110050","DOI":"10.1016\/j.intimp.2023.110050","article-title":"The efficacy and safety of dupilumab combined with methylprednisolone in the treatment of bullous pemphigoid in China","volume":"118","author":"Qi","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5070\/D327955136","article-title":"Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: A case report and review of the literature","volume":"27","author":"Klepper","year":"2021","journal-title":"Dermatol. Online J."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e15648","DOI":"10.1111\/dth.15648","article-title":"Dupilumab combined with low-dose systemic steroid therapy improves efficacy and safety for bullous pemphigoid","volume":"35","author":"Yang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Foerster, Y., Sollfrank, L., Rechtien, L., Harrer, T., Berking, C., and Sticherling, M. (2023). Case report: Bullous pemphigoid in HIV-1-positive patients: Interplay or coincidence? A case series and review of the literature. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1179294"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1111\/ijd.16525","article-title":"Dupilumab as a novel therapy for bullous pemphigoid","volume":"62","author":"Zhang","year":"2023","journal-title":"Int. J. Dermatol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"685","DOI":"10.36849\/JDD.7196","article-title":"Erythrodermic Bullous Pemphigoid in Skin of Color Treated with Dupilumab","volume":"22","author":"Sanfilippo","year":"2023","journal-title":"J. Drugs Dermatol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/1346-8138.16428","article-title":"Treatment of bullous pemphigoid with dupilumab: Dupilumab exerts its effect by primarily suppressing T-helper 2 cytokines","volume":"49","author":"Takamura","year":"2022","journal-title":"J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"adv12324","DOI":"10.2340\/actadv.v103.12324","article-title":"Effect of Dupilumab on Generalized Verrucosis in Refractory Bullous Pemphigoid","volume":"103","author":"Wang","year":"2023","journal-title":"Acta Derm.-Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Wang, S.-H., Shan, Y., Li, S.-Z., and Zuo, Y.-G. (2023). Anti-interleukin 4 receptor \u03b1 antibody for the treatment of Chinese bullous pemphigoid patients with diverse comorbidities and a 1-year follow-up: A monocentric real-world study. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1165106"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e15541","DOI":"10.1111\/dth.15541","article-title":"Case report: Dupilumab for the treatment of bullous pemphigoid","volume":"35","author":"Wang","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2147\/CCID.S415019","article-title":"Successful Treatment of Psoriasis Combined with Bullous Pemphigoid with Dupilumab: A Case Report","volume":"16","author":"Liu","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e13488","DOI":"10.1111\/srt.13488","article-title":"Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid","volume":"29","author":"Margiotta","year":"2023","journal-title":"Skin Res. Technol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e15890","DOI":"10.1111\/dth.15890","article-title":"A severe case of IgA bullous pemphigoid successfully treated with dupilumab","volume":"35","author":"Valenti","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_66","first-page":"e30541","article-title":"The Successful Treatment of COVID-19-Induced Bullous Pemphigoid with Dupilumab","volume":"14","author":"Savoldy","year":"2022","journal-title":"Cureus"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jdcr.2022.09.017","article-title":"Recalcitrant bullous pemphigoid responsive to dupilumab in an adolescent patient","volume":"29","author":"Zhou","year":"2022","journal-title":"JAAD Case Rep."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1111\/ced.14765","article-title":"Treatment of pemphigoid gestationis with dupilumab","volume":"46","author":"Loughlin","year":"2021","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/ajd.13692","article-title":"Dupilumab successfully treated refractory bullous pemphigoid with early clinical manifestations imitating atopic dermatitis: A case letter","volume":"62","author":"Zhang","year":"2021","journal-title":"Australas. J. Dermatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamadermatol.2018.2526","article-title":"Dupilumab for the Treatment of Recalcitrant Bullous Pemphigoid","volume":"154","author":"Kaye","year":"2018","journal-title":"JAMA Dermatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"e15727","DOI":"10.1111\/dth.15727","article-title":"Severe pemphigoid nodularis successfully treated with dupilumab","volume":"35","author":"Jendoubi","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_72","first-page":"1","article-title":"Dupilumab as a treatment for cutaneous immune-related adverse events induced by immune checkpoint inhibitors: A case series and review of the literature","volume":"11","author":"Fournier","year":"2023","journal-title":"SAGE Open Med. Case Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"888","DOI":"10.25259\/IJDVL_1149_2022","article-title":"Dupilumab as monotherapy for bullous pemphigoid with multiple underlying diseases: A report of two cases","volume":"89","author":"Chen","year":"2023","journal-title":"Indian J. Dermatol. Venereol. Leprol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4844\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:37:51Z","timestamp":1760110671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/16\/4844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":73,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcm13164844"],"URL":"https:\/\/doi.org\/10.3390\/jcm13164844","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}